Despite uncertainty around Brexit, the United Kingdom remains one of the world’s premier life science investment destinations, with heavyweight medical science infrastructure and a reputation for elite-level innovation.
In this report, key industry stakeholders explore how the nation is attempting to re-position itself, noting both the challenges and the opportunities of a unique situation.
Topics include government’s ambitious “Life Sciences Industrial Strategy” and subsequent “Sector Deal” with industry, multinationals committed to continuous investment in British R&D, as well as the inimitable National Health Service and its interplay with the country’s innovation ecosystem.
Other key issues are the prominent role played by British medical research charities, “catapult” organizations set up to propel innovation forward, continuing attractiveness of the UK as a manufacturing base, and a regional focus on what the country has to offer both inside and outside of the “Golden Triangle” of Oxford, Cambridge and London.
This report features the contributions of NHS England CEO Simon Stevens; Parliamentary Under Secretary of State for Health Lord O’Shaughnessy; the country managers of Roche, Novartis, Pfizer, and AstraZeneca; as well as a host of other actors across the innovative biotech and cell therapy spectrum.